Head-to-head · Cost-Efficiency Index
Found vs Invigor Medical
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Found
Cost-first shoppers who also want behavior-change coaching bundled with the medication.
Visit FoundInvigor Medical
Value shoppers who want competitive pricing on both molecules plus a wider wellness/hormone program on one account.
Visit Invigor MedicalThe verdict
Found and Invigor Medical tie on the Cost-Efficiency Index at 88/100, so neither wins outright on the numbers. For most shoppers we'd start with Found (ranked #3, a hair above #4) — Cost-first shoppers who also want behavior-change coaching bundled with the medication. But Invigor Medical is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Found.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Found | Invigor Medical |
|---|---|---|
| Cost-Efficiency Index | 88/100 | 88/100 |
| Semaglutide / mo | $129/mo | $199/mo |
| Tirzepatide / mo | $129/mo | $339/mo |
| Semaglutide / yr (modeled) | $1,548 | $2,388 |
| Tirzepatide / yr (modeled) | $1,548 | $4,068 |
| Coverage | All 50 states | Not disclosed |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank on the board | #3 | #4 |
Found
88/100Where the value is
- Lowest cost-per-month on the board — identical $129 on both molecules
- Nationwide
- Strong behavior-change program adds value
The tradeoffs
- Coaching subscription can't be unbundled, which reduces contract flexibility
- Compounded only
Invigor Medical
88/100Where the value is
- Competitive mid-market pricing on both semaglutide and tirzepatide
- Long-running operator with a broad catalog that can consolidate spend
- Both molecules published up front for easy cost modeling
The tradeoffs
- Does not publish an explicit states-served list, so access is a variable in the model
- Compounded only
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.